Arca
Skip to content
Tools
Tools

Anemia

Drug research and approvals for anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 510 studies of anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 22 approved and 34 open orphan designations naming it, and the EU has 13 authorised medicines for it.

  • Recruiting worldwide: 510
  • Trials authorized in Canada: 41
  • FDA orphan approvals: 22
  • EU medicines: 13

Recruiting now

Newest posted first, of 510 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 57

Phase 3 12 of 18

Phase 2 12 of 15

Phase 1 or earlier 12 of 25

How its trials ended

1,685 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 481 whose ending is known, 49% met their primary endpoint, 7% missed it and 44% stopped early.

  • Completed, result not reported72243%
  • Ongoing28517%
  • Met its primary endpoint23514%
  • Status unknown19712%
  • Stopped: other or unclear996%
  • Stopped: enrollment or feasibility644%
  • Missed its primary endpoint362%
  • Stopped: sponsor or business decision251%
  • Stopped: lack of efficacy161%
  • Stopped: funding4<1%
  • Stopped: safety2<1%

Trials authorized in Canada

The 10 newest of 41; search them all in Canada trials
Nov 13, 2026A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and…EPRA-0322Epok Therapeutics Inc.Pending
Jul 22, 2026A phase 3, double-blind, randomized trial evaluating the efficacy and safety of elritercept (TAK-226) compared to placebo in participants with myelofibrosis…Elritercept (TAK-226, KER-050)Takeda Pharmaceuticals USAPending
Dec 9, 2025A phase 2/3 randomized, multicenter study of osivelotor administered orally to adult and adolescent participants with sickle cell diseaseOsivelotor (PF-07940367, GBT021601)PfizerPending
May 7, 2025A randomized, double-blind, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of aln-cfb, an…Aln-cfb (ALN-1725763)RegeneronOngoing
Mar 24, 2025A phase 2, randomized, open-label, study of momelotinib in participants with anemia due to low-risk myelodysplastic syndromeMomelotinib (GSK3070785)GSKOngoing
Jun 17, 2024A phase III randomized trial comparing unrelated donor bone marrow transplantation with immune suppressive therapy for newly diagnosed pediatric and young…FludarabineNational Marrow Donor ProgramClosed
May 22, 2024Optima study : optimizing hydroxyurea dosage with pharmakokinetic in patients suffering of moderate to severe sickle cell anemia.HydroxyureaDr. Yves PastoreOngoing
Nov 8, 2023The effect of intravenous iron in treating anemia in ovarian cancer patients in saskatchewan: a phase-iii, open-label, randomized trialIronUniversity of SaskatchewanClosed
Aug 28, 2023A phase 1/2, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral nuvisertib (TP-3654) in patients with intermediate or…Nuvisertib (TP-3654) / MomelotinibSumitomo PharmaPending
Jun 30, 2023A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) vs epoetin alfa for the treatment of anemia due to revised…Luspatercept (ace 536) / Epoetin alfaBristol-Myers SquibbOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 56
Aug 24, 2026ImaavyTreatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously…Janssen Research & Development, LLCApproved
Dec 23, 2025AqvesmeTreatment of anemia in adults with alpha- or beta-thalassemiaAgios Pharmaceuticals, Inc.Approved
Dec 5, 2025OmisirgeTreatment of adults and pediatric patients 6 years of age and older with severe aplastic anemia (SAA) following reduced intensity…Gamida Cell Ltd.Approved
Dec 23, 2024XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients 6 months of age and older with…Nova Laboratories LimitedApproved
Jun 6, 2024RyteloTreatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4…Geron CorporationApproved
Apr 4, 2024XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less…Nova Laboratories LimitedApproved
Sep 15, 2023OjjaaraTreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and…GlaxoSmithKlineApproved
Aug 28, 2023ReblozylTreatment of anemia without previous erythropoiesis stimulating agent use (ESA-naive) in adult patients with very low- to intermediate-risk…Celgene Corporation, a Bristol-Myers Squibb CompanyApproved
Jan 25, 2023EnjaymoTreatment of hemolysis in adults with cold agglutinin disease (CAD)Recordati Rare Diseases Inc.Approved
Feb 17, 2022PyrukyndTreatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiencyAgios Pharmaceuticals, Inc.Approved
Feb 4, 2022EnjaymoTo decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)Recordati Rare Diseases Inc.Approved
Apr 3, 2020ReblozylREBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units…Celgene Corporation, a Bristol-Myers Squibb CompanyApproved
Nov 8, 2019ReblozylREBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC)…Celgene CorporationApproved
Nov 16, 2018PromactaPROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2…Novartis Pharmaceuticals Corp.Approved
Dec 21, 2017SiklosTo reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older,…Theravia PharmaApproved

Medicines authorised in the EU

Newest first
Mar 7, 2025RyteloImetelstat · orphanGeron Netherlands B.V.EMA ↗
Aug 18, 2021EvrenzoRoxadustatAstellas Pharma Europe B.V.EMA ↗
Jun 25, 2020ReblozylLuspatercept · orphanBristol Myers Squibb Pharma EEIGEMA ↗
Jul 1, 2019XromiHydroxycarbamideLipomed GmbHEMA ↗
Feb 18, 2016FeraccruFerric maltolNorgine B.V.EMA ↗
Dec 18, 2007SilapoEpoetin zeta · biosimilarStada Arzneimittel AGEMA ↗
Dec 18, 2007RetacritEpoetin zeta · biosimilarPfizer Europe MA EEIGEMA ↗
Aug 28, 2007BinocritEpoetin alfa · biosimilarSandoz GmbHEMA ↗
Aug 27, 2007Epoetin Alfa HexalEpoetin alfa · biosimilarHexal AGEMA ↗
Aug 27, 2007AbseamedEpoetin alfa · biosimilarMedice Arzneimittel Pütter GmbH Co. KGEMA ↗
Jul 20, 2007MirceraMethoxy polyethylene glycol-epoetin betaRoche Registration GmbHEMA ↗
Jun 29, 2007SiklosHydroxycarbamideTheraviaEMA ↗
Jun 8, 2001AranespDarbepoetin alfaAmgen Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.